ArticleDiabetes technology & therapeutics2022
Impact of Temporary Glycemic Target Use in the Hybrid and Advanced Hybrid Closed-Loop Systems.
Article in Diabetes technology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.Therapeutic advances in endocrinology and metabolism · 2026Article
- Safety and glycaemic control during exercise with the MiniMed™ 780G: A narrative review of evidence from lab to real world.Diabetes, obesity & metabolism · 2026Review
- Effect of Atmospheric Temperature Variations on Glycemic Patterns of Patients with Type 1 Diabetes: Analysis as a Function of Different Therapeutic Treatments.International journal of environmental research and public health · 2025Article
- Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.AAPS PharmSciTech · 2025Review
- Use of the temporary glycemic target feature in the medtronic MiniMed™ 780G advanced hybrid closed loop system: a real-world evidence study.Acta diabetologica · 2025Observational
- Safety, Metabolic and Psychological Outcomes of Medtronic MiniMed 780G™ in Children, Adolescents and Young Adults: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- New therapies towards a better glycemic control in youths with type 1 diabetes.Pharmacological research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 3 countries.
Funding
Abstract
The Medtronic advanced hybrid closed-loop (AHCL) and MiniMed™ 670G hybrid closed-loop (HCL) systems provide the option to temporarily increase the glucose target to 150 mg/dL (8.3 mmol/L). This analysis investigated the efficacy of the AHCL compared with that of the HCL after the use of this setting. Data from 60 participants in the Fuzzy Logic Automated Insulin Regulation (FLAIR) study were used to compare the AHCL and HCL systems after the use of the temporary target (TT), and during analogous periods where this setting was not used. Differences in time in range 70-180 mg/dL between the systems were similar after the use of the TT setting and during analogous non-TT periods (interaction
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.